Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2

Active, not recruiting

• Conditions: Stage IIIC Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
• Interventions: Drug: Nogapendekin Alfa; Dietary Supplement: Cobalamin; Biological: Pembrolizumab; Drug: Dexamethasone; Drug: Docetaxel; Dietary Supplement: Folic Acid; Drug: Gemcitabine; Drug: Pemetrexed; Biological: Ramucirumab

• Registration Number: NCT05096663
• Lead Sponsor: SWOG Cancer Research Network

Brief Summary

This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Natural killer cells, part of our immune system, are always on alert and ready to defend our bodies from many kinds of infection or rogue cells, such as those that cause cancer. N-803 (ALT-803) may activate natural killer cells so that they can stimulate an immune response to help fight cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving N-803 (ALT-803) and pembrolizumab may help shrink and stabilize lung cancer or prevent it from returning.

Detailed Description

PRIMARY OBJECTIVES:

I. To compare overall survival (OS) between participants randomized to nogapendekin alfa (N-803 \[ALT-803\]) + pembrolizumab versus standard of care therapy. (Primary Resistance Cohort) II. To compare overall survival (OS) between participants randomized to N-803 (ALT-803) + pembrolizumab versus standard of care therapy. (Acquired Resistance Cohort)

SECONDARY OBJECTIVES:

I. To compare investigator assessed progression-free survival (IA-PFS) with confirmation of progression by immune response criteria between the treatment arms.

II. To compare investigator assessed progression-free survival (IA-PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between the treatment arms.

III. To compare the response rates between the arms. IV. To evaluate duration of response (DoR) among responders. V. To evaluate the frequency and severity of toxicities within each treatment arm.

TRANSLATIONAL MEDICINE OBJECTIVE:

I. To establish a blood repository to pursue future studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive standard of care consisting of docetaxel intravenously (IV) over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive pembrolizumab IV over 30 minutes and nogapendekin alfa subcutaneously (SC) on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients then receive nogapendekin alfa SC on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 2 years.

Study Timeline

• Study First Submitted: 2021-10-14
• Study First Submitted QC: 2021-10-14
• Study First Posted: 2021-10-27
• Study Start: 2022-03-15
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-12
• Last Update Posted: 2025-05-15
• Primary Completion: 2027-02-01
• Study Completion: 2027-12-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

• Participants must have been assigned to S1800D by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1800D is determined by the LUNGMAP or S1400 protocol

• Participants must have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI). Measurable disease must be assessed within 28 days prior to randomization. Non-measurable disease must be assessed within 42 days prior to randomization. The CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1)

• Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study randomization

• Participants with spinal cord compression or brain metastases must have received local treatment to these metastases and remained clinically controlled and asymptomatic for at least 7 days following stereotactic radiation and/or 14 days following whole brain radiation, and prior to sub-study randomization

• Participants with spinal cord compression or brain metastases must not have residual neurological dysfunction, unless no further recovery is expected, and the participant has been stable on weaning doses of corticosteroids (=< 10 mg daily prednisone or equivalent) prior to sub-study randomization

• Participants must have progressed (in the opinion of the treating investigator) following the most recent line of therapy for non-small cell lung cancer (NSCLC)

• Participants with a known sensitizing mutation for which an FDA-approved targeted therapy for NSCLC exists (e.g. EGFR, ALK gene fusions, ROS1, BRAF, RET, NTRK, and MET sensitizing mutations), must have previously received at least one of the approved therapy(s)

• Participants must have received exactly one line of anti-PD-1 or anti-PD-L1 therapy for advanced disease (stage IV or recurrent, or stage III in certain circumstances outlined below) given alone or in combination with platinum-based chemotherapy. Participants must have experienced disease progression during or after this regimen

  • Continuing the same agent(s) after progression counts as a single line of therapy. However, a change or addition in agent(s) after progression (e.g. the addition of chemotherapy to anti-PD-1 monotherapy after progression) counts as a subsequent line of therapy and would exclude the participant

  • For participants who received consolidation anti-PD-1 or anti-PD-L1 therapy following concurrent chemoradiation for Stage III disease as their only line of anti-PD-1 or anti-PD-L1 therapy:

    • If they experienced disease progression less than (<) 365 days from the first date of anti-PD-1 or anti-PD-L1 therapy, this counts as the single line of anti-PD-1 or anti-PD-L1 therapy for advanced disease
    • If they experienced disease progression more than or equal to (>=) 365 days from the first date of anti-PD-1 or anti-PD-L1 therapy, this is not considered a line of anti-PD-1 or anti-PD-L1 therapy for advanced disease

• Participants must have recovered (=< grade 1) from any side effects of prior therapy, except for alopecia

• Participants must be able to safely receive at least one of the investigator's choice of standard of care regimens, per the current FDA-approved package insert

  • Note: Pemetrexed is not FDA-approved for squamous cell NSCLC and must not be used to treat participants with squamous cell NSCLC

• Absolute neutrophil count (ANC) >= 1.5 x 10^3/uL (obtained within 28 days prior to sub-study randomization)

• Platelet count >= 100 x 10^3/uL(obtained within 28 days prior to sub-study randomization)

• Hemoglobin >= 9 g/dL (obtained within 28 days prior to sub-study randomization)

• Serum bilirubin =< institutional upper limit of normal (IULN) (within 28 days prior to sub-study randomization). For participants with liver metastases, bilirubin must be =< 5 x IULN

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 x IULN (within 28 days prior to sub-study randomization). For participants with liver metastases, ALT and AST must be =< 5 x IULN

• Serum creatinine =< the IULN or calculated creatinine clearance >= 50 mL/min using Cockcroft-Gault formula. This specimen must have been drawn and processed within 28 days prior to sub-study randomization

• Participants' most recent Zubrod performance status must be 0-1 and be documented within 28 days prior to sub-study randomization

• Participants must have history and physical exam must be obtained within 28 days prior to sub-study randomization

• Participants with known human immunodeficiency virus (HIV) infection must be receiving anti-retroviral therapy and have an undetectable viral load at their most recent viral load test within 6 months prior to sub-study randomization

• Participants must also be offered participation in banking and in the correlative studies for collection and future use of specimens

• Note: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

  • Participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines

Exclusion Criteria

• Participants must not have leptomeningeal disease that requires CNS-specific treatment prior to registration and must not be planning to receive the CNS-specific treatment through the first cycle of the protocol therapy

• Participants must not have experienced the following:

  • Any grade 3 or worse immune-related adverse event (irAE). Exception: asymptomatic nonbullous/nonexfoliative rash
  • Any unresolved grade 2 irAE
  • Any toxicity that led to permanent discontinuation of prior anti-PD-1/PD-L1 immunotherapy
  • Exception to the above: Toxicities of any grade that requires replacement therapy and has stabilized on therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) are allowed

• Participants must not have any history of organ transplant that requires use of immunosuppressives

• Participants must not have history of (non-infectious) pneumonitis that required steroids or current pneumonitis/interstitial lung disease

• Participants must not have any known allergy or reaction to any component of the investigational formulations. If there is a known allergy or reaction to standard of care formulations, participants must be able to safely receive at least one of the standard of care options

• Participants must not have any grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., participants with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, and myocardial infarction within 6 months prior to sub-study randomization, or serious uncontrolled cardiac arrhythmia

• Participants must not have experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to sub-study randomization

• Participants must not have an active or uncontrolled infection in the opinion of the treating investigator

• Participants must not have a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen

• Participants must not have any of following:

  • Cirrhosis at a level of Child-Pugh B (or worse)
  • Cirrhosis (any degree) and a history of hepatic encephalopathy
  • Or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis

• Participants must not have received anti-CTLA4 therapy (e.g. ipilimumab, tremelimumab), or other immune-modulatory therapy (e.g. anti-TIM-3, anti-LAG-3, anti-GITR, IL-2, IL-15)

• Participants must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to sub-study randomization

• Participants must not have received any radiation therapy within 14 days prior to sub-study randomization

• Participants must not have received nitrosoureas or mitomycin-c within 42 days prior to sub-study randomization

• Participants must not have received systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 7 days prior to sub-study randomization. Inhaled or topical steroids, and adrenal replacement doses =< 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease

• Participants must not have received a live attenuated vaccination within 28 days prior to sub-study randomization. All COVID-19 vaccines that have received Food and Drug Administration (FDA) approval or FDA emergency use authorization are acceptable

• Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study

• Participants must not have had a major surgery within 14 days prior to sub-study randomization. Participant must have fully recovered from the effects of prior surgery in the opinion of the treating investigator

• Participants must not have an active autoimmune disease that has required systemic treatment within two years prior to sub-study randomization (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed

• Participants must not have any history of primary immunodeficiency

• Participants must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use an effective contraceptive method during the study and 4 months after completion of study treatment. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures during the study and 4 months after study completion

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm B (pembrolizumab, nogapendekin alfa)	Nogapendekin Alfa	Patients receive pembrolizumab IV over 30 minutes and nogapendekin alfa SC on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients then receive nogapendekin alfa SC on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Arm A (standard of care)	Ramucirumab	Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Arm B (pembrolizumab, nogapendekin alfa)	Pembrolizumab	Patients receive pembrolizumab IV over 30 minutes and nogapendekin alfa SC on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients then receive nogapendekin alfa SC on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Arm A (standard of care)	Cobalamin	Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Arm A (standard of care)	Folic Acid	Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Arm A (standard of care)	Dexamethasone	Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Arm A (standard of care)	Docetaxel	Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Arm A (standard of care)	Gemcitabine	Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Arm A (standard of care)	Pemetrexed	Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Overall survival	Up to 2 years	Will be compared between the arms using the combination weighted/unweighted log-rank test statistic (as utilized in S1800A) with statistical significance at the 1-sided 10% level.

Secondary Outcome Measures

Name	Time	Method
Investigator-assessed progression-free survival (IA-PFS)	From date of sub-study randomization to date of first documentation of potential immune-response confirmed progression, or death due to any cause, assessed up to 2 years	Will be compared between the arms using the combination weighted/unweighted log-rank test statistic (as utilized in S1800A) with statistical significance at the 1-sided 10% level.
Duration of response (DoR)	From date of first documentation of response (complete response or partial response) to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause, assessed up to 2 years

Trial Locations

Locations (349)

Kaiser Permanente West Los Angeles; 🇺🇸 Los Angeles, California, United States

Illinois CancerCare-Princeton; 🇺🇸 Princeton, Illinois, United States

UPMC-Mercy Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

Mission Cancer and Blood - Laurel; 🇺🇸 Des Moines, Iowa, United States

Indiana University/Melvin and Bren Simon Cancer Center; 🇺🇸 Indianapolis, Indiana, United States

OptumCare Cancer Care at Fort Apache; 🇺🇸 Las Vegas, Nevada, United States

Cedars Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Kaiser Permanente Medical Center - Santa Clara; 🇺🇸 Santa Clara, California, United States

Kaiser Permanente-Vallejo; 🇺🇸 Vallejo, California, United States

Torrance Memorial Physician Network - Cancer Care; 🇺🇸 Torrance, California, United States

Palo Alto Medical Foundation-Santa Cruz; 🇺🇸 Santa Cruz, California, United States

Palo Alto Medical Foundation-Sunnyvale; 🇺🇸 Sunnyvale, California, United States

Kaiser Permanente-Walnut Creek; 🇺🇸 Walnut Creek, California, United States

Northside Hospital - Duluth; 🇺🇸 Duluth, Georgia, United States

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler; 🇺🇸 Savannah, Georgia, United States

Carle Physician Group-Effingham; 🇺🇸 Effingham, Illinois, United States

Crossroads Cancer Center; 🇺🇸 Effingham, Illinois, United States

Northeast Georgia Medical Center-Gainesville; 🇺🇸 Gainesville, Georgia, United States

Illinois CancerCare-Dixon; 🇺🇸 Dixon, Illinois, United States

Illinois CancerCare-Eureka; 🇺🇸 Eureka, Illinois, United States

Illinois CancerCare-Galesburg; 🇺🇸 Galesburg, Illinois, United States

Illinois CancerCare-Ottawa Clinic; 🇺🇸 Ottawa, Illinois, United States

Cancer Care Center of O'Fallon; 🇺🇸 O'Fallon, Illinois, United States

Northwestern Medicine Lake Forest Hospital; 🇺🇸 Lake Forest, Illinois, United States

Illinois CancerCare-Macomb; 🇺🇸 Macomb, Illinois, United States

Southern Illinois University School of Medicine; 🇺🇸 Springfield, Illinois, United States

Springfield Clinic; 🇺🇸 Springfield, Illinois, United States

Illinois CancerCare - Washington; 🇺🇸 Washington, Illinois, United States

Mary Greeley Medical Center; 🇺🇸 Ames, Iowa, United States

McFarland Clinic PC - Ames; 🇺🇸 Ames, Iowa, United States

McFarland Clinic PC-Trinity Cancer Center; 🇺🇸 Fort Dodge, Iowa, United States

Greater Regional Medical Center; 🇺🇸 Creston, Iowa, United States

Mercy Medical Center-West Lakes; 🇺🇸 West Des Moines, Iowa, United States

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

AdventHealth Infusion Center Asheville; 🇺🇸 Asheville, North Carolina, United States

Memorial Medical Center - Las Cruces; 🇺🇸 Las Cruces, New Mexico, United States

Cone Health Cancer Center at Alamance Regional; 🇺🇸 Burlington, North Carolina, United States

Cone Health Cancer Center; 🇺🇸 Greensboro, North Carolina, United States

Duke Women's Cancer Care Raleigh; 🇺🇸 Raleigh, North Carolina, United States

Adena Regional Medical Center; 🇺🇸 Chillicothe, Ohio, United States

The Mark H Zangmeister Center; 🇺🇸 Columbus, Ohio, United States

Cleveland Clinic Cancer Center Mansfield; 🇺🇸 Mansfield, Ohio, United States

OhioHealth Marion General Hospital; 🇺🇸 Marion, Ohio, United States

Licking Memorial Hospital; 🇺🇸 Newark, Ohio, United States

Hillcrest Hospital Cancer Center; 🇺🇸 Mayfield Heights, Ohio, United States

Southern Ohio Medical Center; 🇺🇸 Portsmouth, Ohio, United States

ProMedica Flower Hospital; 🇺🇸 Sylvania, Ohio, United States

Cleveland Clinic Cancer Center Strongsville; 🇺🇸 Strongsville, Ohio, United States

Saint Ann's Hospital; 🇺🇸 Westerville, Ohio, United States

Cleveland Clinic Wooster Family Health and Surgery Center; 🇺🇸 Wooster, Ohio, United States

UPMC Camp Hill; 🇺🇸 Camp Hill, Pennsylvania, United States

Carlisle Regional Cancer Center; 🇺🇸 Carlisle, Pennsylvania, United States

WellSpan Medical Oncology and Hematology; 🇺🇸 Chambersburg, Pennsylvania, United States

UPMC Pinnacle Cancer Center/Community Osteopathic Campus; 🇺🇸 Harrisburg, Pennsylvania, United States

Ephrata Cancer Center; 🇺🇸 Ephrata, Pennsylvania, United States

Oncology Hematology Associates; 🇺🇸 Greenville, Pennsylvania, United States

IRMC Cancer Center; 🇺🇸 Indiana, Pennsylvania, United States

University of Pittsburgh Cancer Institute (UPCI); 🇺🇸 Pittsburgh, Pennsylvania, United States

Cancer Care Associates of York; 🇺🇸 York, Pennsylvania, United States

Pottstown Hospital; 🇺🇸 Pottstown, Pennsylvania, United States

UPMC Memorial; 🇺🇸 York, Pennsylvania, United States

UT Southwestern/Simmons Cancer Center-Dallas; 🇺🇸 Dallas, Texas, United States

UT Southwestern Clinical Center at Richardson/Plano; 🇺🇸 Richardson, Texas, United States

UT Southwestern/Simmons Cancer Center-Fort Worth; 🇺🇸 Fort Worth, Texas, United States

Kaiser Permanente-Burke Medical Center; 🇺🇸 Burke, Virginia, United States

Kaiser Permanente San Leandro; 🇺🇸 San Leandro, California, United States

Minneapolis VA Medical Center; 🇺🇸 Minneapolis, Minnesota, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Sanford Joe Lueken Cancer Center; 🇺🇸 Bemidji, Minnesota, United States

Olathe Health Cancer Center; 🇺🇸 Olathe, Kansas, United States

University of Kansas Hospital-Westwood Cancer Center; 🇺🇸 Westwood, Kansas, United States

Essentia Health Cancer Center; 🇺🇸 Duluth, Minnesota, United States

Essentia Health Hibbing Clinic; 🇺🇸 Hibbing, Minnesota, United States

Essentia Health - Deer River Clinic; 🇺🇸 Deer River, Minnesota, United States

Sanford Bismarck Medical Center; 🇺🇸 Bismarck, North Dakota, United States

University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

Kaiser Permanente-Woodlawn Medical Center; 🇺🇸 Baltimore, Maryland, United States

UPMC Western Maryland; 🇺🇸 Cumberland, Maryland, United States

Kaiser Permanente - Largo Medical Center; 🇺🇸 Largo, Maryland, United States

University of Oklahoma Health Sciences Center; 🇺🇸 Oklahoma City, Oklahoma, United States

Mercy Hospital Oklahoma City; 🇺🇸 Oklahoma City, Oklahoma, United States

Kaiser Permanente Northwest; 🇺🇸 Portland, Oregon, United States

Palo Alto Medical Foundation-Fremont; 🇺🇸 Fremont, California, United States

Kaiser Permanente-Fontana; 🇺🇸 Fontana, California, United States

Kaiser Permanente-Irvine; 🇺🇸 Irvine, California, United States

Kaiser Permanente-Baldwin Park; 🇺🇸 Baldwin Park, California, United States

Kaiser Permanente - Harbor City; 🇺🇸 Harbor City, California, United States

Kaiser Permanente-Roseville; 🇺🇸 Roseville, California, United States

Kaiser Permanente-Santa Teresa-San Jose; 🇺🇸 San Jose, California, United States

Sutter Auburn Faith Hospital; 🇺🇸 Auburn, California, United States

Kaiser Permanente-San Diego Zion; 🇺🇸 San Diego, California, United States

Veterans Affairs Medical Center - San Francisco; 🇺🇸 San Francisco, California, United States

Tower Cancer Research Foundation; 🇺🇸 Beverly Hills, California, United States

Kaiser Permanente Los Angeles Medical Center; 🇺🇸 Los Angeles, California, United States

Memorial Medical Center; 🇺🇸 Springfield, Illinois, United States

Kaiser Permanente-Oakland; 🇺🇸 Oakland, California, United States

Kaiser Permanente-Bellflower; 🇺🇸 Bellflower, California, United States

Veterans Administration Medical Center - Birmingham; 🇺🇸 Birmingham, Alabama, United States

Kaiser Permanente-Anaheim; 🇺🇸 Anaheim, California, United States

Kaiser Permanente - Panorama City; 🇺🇸 Panorama City, California, United States

Kaiser Permanente-Ontario; 🇺🇸 Ontario, California, United States

Kaiser Permanente-Woodland Hills; 🇺🇸 Woodland Hills, California, United States

Illinois CancerCare-Carthage; 🇺🇸 Carthage, Illinois, United States

Carle Physician Group-Mattoon/Charleston; 🇺🇸 Mattoon, Illinois, United States

Edward Hines Jr VA Hospital; 🇺🇸 Hines, Illinois, United States

Palo Alto Medical Foundation Health Care; 🇺🇸 Palo Alto, California, United States

Eisenhower Medical Center; 🇺🇸 Rancho Mirage, California, United States

Kaiser Permanente-South San Francisco; 🇺🇸 South San Francisco, California, United States

Kaiser Permanente-Riverside; 🇺🇸 Riverside, California, United States

California Pacific Medical Center-Pacific Campus; 🇺🇸 San Francisco, California, United States

Kaiser Permanente-San Francisco; 🇺🇸 San Francisco, California, United States

Centralia Oncology Clinic; 🇺🇸 Centralia, Illinois, United States

Carle on Vermilion; 🇺🇸 Danville, Illinois, United States

Illinois CancerCare-Canton; 🇺🇸 Canton, Illinois, United States

Northside Hospital; 🇺🇸 Atlanta, Georgia, United States

Cancer Care Specialists of Illinois - Decatur; 🇺🇸 Decatur, Illinois, United States

Illinois CancerCare-Bloomington; 🇺🇸 Bloomington, Illinois, United States

Illinois CancerCare-Pekin; 🇺🇸 Pekin, Illinois, United States

The Carle Foundation Hospital; 🇺🇸 Urbana, Illinois, United States

University of Iowa Healthcare Cancer Services Quad Cities; 🇺🇸 Bettendorf, Iowa, United States

McFarland Clinic PC-Boone; 🇺🇸 Boone, Iowa, United States

Harold Alfond Center for Cancer Care; 🇺🇸 Augusta, Maine, United States

Lafayette Family Cancer Center-EMMC; 🇺🇸 Brewer, Maine, United States

Lawrence Memorial Hospital; 🇺🇸 Lawrence, Kansas, United States

McFarland Clinic PC-Jefferson; 🇺🇸 Jefferson, Iowa, United States

Salina Regional Health Center; 🇺🇸 Salina, Kansas, United States

Oncology Associates at Mercy Medical Center; 🇺🇸 Cedar Rapids, Iowa, United States

Owensboro Health Mitchell Memorial Cancer Center; 🇺🇸 Owensboro, Kentucky, United States

McFarland Clinic PC-Marshalltown; 🇺🇸 Marshalltown, Iowa, United States

University of Kansas Health System Saint Francis Campus; 🇺🇸 Topeka, Kansas, United States

University of Kansas Hospital-Indian Creek Campus; 🇺🇸 Overland Park, Kansas, United States

HaysMed University of Kansas Health System; 🇺🇸 Hays, Kansas, United States

Ascension Providence Hospitals - Novi; 🇺🇸 Novi, Michigan, United States

Abbott-Northwestern Hospital; 🇺🇸 Minneapolis, Minnesota, United States

Unity Hospital; 🇺🇸 Fridley, Minnesota, United States

Park Nicollet Clinic - Saint Louis Park; 🇺🇸 Saint Louis Park, Minnesota, United States

Essentia Health Virginia Clinic; 🇺🇸 Virginia, Minnesota, United States

Missouri Baptist Medical Center; 🇺🇸 Saint Louis, Missouri, United States

Sainte Genevieve County Memorial Hospital; 🇺🇸 Sainte Genevieve, Missouri, United States

Siteman Cancer Center at Saint Peters Hospital; 🇺🇸 Saint Peters, Missouri, United States

Missouri Baptist Sullivan Hospital; 🇺🇸 Sullivan, Missouri, United States

Virtua Voorhees; 🇺🇸 Voorhees, New Jersey, United States

Sanford Roger Maris Cancer Center; 🇺🇸 Fargo, North Dakota, United States

Renown Regional Medical Center; 🇺🇸 Reno, Nevada, United States

Missouri Baptist Outpatient Center-Sunset Hills; 🇺🇸 Sunset Hills, Missouri, United States

Solinsky Center for Cancer Care; 🇺🇸 Manchester, New Hampshire, United States

New Hampshire Oncology Hematology PA-Concord; 🇺🇸 Concord, New Hampshire, United States

Siteman Cancer Center at Christian Hospital; 🇺🇸 Saint Louis, Missouri, United States

Bozeman Deaconess Hospital; 🇺🇸 Bozeman, Montana, United States

Virtua Samson Cancer Center; 🇺🇸 Moorestown, New Jersey, United States

AdventHealth Hendersonville; 🇺🇸 Hendersonville, North Carolina, United States

Randolph Hospital; 🇺🇸 Asheboro, North Carolina, United States

Presbyterian Rust Medical Center/Jorgensen Cancer Center; 🇺🇸 Rio Rancho, New Mexico, United States

AdventHealth Infusion Center Haywood; 🇺🇸 Clyde, North Carolina, United States

Annie Penn Memorial Hospital; 🇺🇸 Reidsville, North Carolina, United States

Cone Heath Cancer Center at Mebane; 🇺🇸 Mebane, North Carolina, United States

Cleveland Clinic Mercy Hospital; 🇺🇸 Canton, Ohio, United States

Cleveland Clinic Cancer Center/Fairview Hospital; 🇺🇸 Cleveland, Ohio, United States

Durham VA Medical Center; 🇺🇸 Durham, North Carolina, United States

Strecker Cancer Center-Belpre; 🇺🇸 Belpre, Ohio, United States

Sanford Broadway Medical Center; 🇺🇸 Fargo, North Dakota, United States

FirstHealth of the Carolinas-Moore Regional Hospital; 🇺🇸 Pinehurst, North Carolina, United States

AdventHealth Infusion Center Weaverville; 🇺🇸 Weaverville, North Carolina, United States

Riverside Methodist Hospital; 🇺🇸 Columbus, Ohio, United States

Grant Medical Center; 🇺🇸 Columbus, Ohio, United States

Doctors Hospital; 🇺🇸 Columbus, Ohio, United States

Duke Raleigh Hospital; 🇺🇸 Raleigh, North Carolina, United States

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States

North Coast Cancer Care; 🇺🇸 Sandusky, Ohio, United States

Adams Cancer Center; 🇺🇸 Gettysburg, Pennsylvania, United States

UPMC Hillman Cancer Center - Passavant - Cranberry; 🇺🇸 Cranberry Township, Pennsylvania, United States

UPMC-Johnstown/John P. Murtha Regional Cancer Center; 🇺🇸 Johnstown, Pennsylvania, United States

Delaware Health Center-Grady Cancer Center; 🇺🇸 Delaware, Ohio, United States

South Pointe Hospital; 🇺🇸 Warrensville Heights, Ohio, United States

Knox Community Hospital; 🇺🇸 Mount Vernon, Ohio, United States

Springfield Regional Cancer Center; 🇺🇸 Springfield, Ohio, United States

Springfield Regional Medical Center; 🇺🇸 Springfield, Ohio, United States

UPMC Hillman Cancer Center Erie; 🇺🇸 Erie, Pennsylvania, United States

UPMC Cancer Center at UPMC McKeesport; 🇺🇸 McKeesport, Pennsylvania, United States

UPMC Cancer Center at UPMC Horizon; 🇺🇸 Farrell, Pennsylvania, United States

UPMC-Passavant Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

Kaiser Permanente Tysons Corner Medical Center; 🇺🇸 McLean, Virginia, United States

UPMC-Coraopolis/Heritage Valley Radiation Oncology; 🇺🇸 Moon, Pennsylvania, United States

Sechler Family Cancer Center; 🇺🇸 Lebanon, Pennsylvania, United States

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion; 🇺🇸 Mechanicsburg, Pennsylvania, United States

Sanford Cancer Center Oncology Clinic; 🇺🇸 Sioux Falls, South Dakota, United States

UPMC Hillman Cancer Center - New Castle; 🇺🇸 New Castle, Pennsylvania, United States

UPMC Cancer Center at UPMC Northwest; 🇺🇸 Seneca, Pennsylvania, United States

Arnold Palmer Cancer Center Medical Oncology Norwin; 🇺🇸 N. Huntingdon, Pennsylvania, United States

UPMC Hillman Cancer Center - Monroeville; 🇺🇸 Monroeville, Pennsylvania, United States

UPMC West Mifflin-Cancer Center Jefferson; 🇺🇸 West Mifflin, Pennsylvania, United States

UPMC Cancer Center-Uniontown; 🇺🇸 Uniontown, Pennsylvania, United States

Temple University Hospital; 🇺🇸 Philadelphia, Pennsylvania, United States

WellSpan Health-York Hospital; 🇺🇸 York, Pennsylvania, United States

UPMC-Saint Clair Hospital Cancer Center; 🇺🇸 Pittsburgh, Pennsylvania, United States

Prisma Health Cancer Institute - Greer; 🇺🇸 Greer, South Carolina, United States

Parkland Memorial Hospital; 🇺🇸 Dallas, Texas, United States

Aurora Cancer Care-Milwaukee West; 🇺🇸 Wauwatosa, Wisconsin, United States

Kaiser Permanente Downtown Commons; 🇺🇸 Sacramento, California, United States

UPMC Hillman Cancer Center at Butler Health System; 🇺🇸 Butler, Pennsylvania, United States

Sutter Medical Center Sacramento; 🇺🇸 Sacramento, California, United States

University of California Davis Comprehensive Cancer Center; 🇺🇸 Sacramento, California, United States

University of Michigan Comprehensive Cancer Center; 🇺🇸 Ann Arbor, Michigan, United States

Saint Joseph Mercy Hospital; 🇺🇸 Ann Arbor, Michigan, United States

Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States

Aurora Sinai Medical Center; 🇺🇸 Milwaukee, Wisconsin, United States

PCR Oncology; 🇺🇸 Arroyo Grande, California, United States

Alta Bates Summit Medical Center-Herrick Campus; 🇺🇸 Berkeley, California, United States

Sutter Solano Medical Center/Cancer Center; 🇺🇸 Vallejo, California, United States

Sutter Roseville Medical Center; 🇺🇸 Roseville, California, United States

Kaiser Permanente-San Marcos; 🇺🇸 San Marcos, California, United States

Presbyterian Intercommunity Hospital; 🇺🇸 Whittier, California, United States

Medical Oncology Hematology Consultants PA; 🇺🇸 Newark, Delaware, United States

Saint Alphonsus Cancer Care Center-Boise; 🇺🇸 Boise, Idaho, United States

Northside Hospital - Gwinnett; 🇺🇸 Lawrenceville, Georgia, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Illinois CancerCare-Kewanee Clinic; 🇺🇸 Kewanee, Illinois, United States

Illinois CancerCare-Peoria; 🇺🇸 Peoria, Illinois, United States

Illinois CancerCare-Peru; 🇺🇸 Peru, Illinois, United States

Mercyhealth Javon Bea Hospital - Rockton; 🇺🇸 Rockford, Illinois, United States

Memorial Hospital of South Bend; 🇺🇸 South Bend, Indiana, United States

Carle Cancer Center; 🇺🇸 Urbana, Illinois, United States

Medical Oncology and Hematology Associates-West Des Moines; 🇺🇸 Clive, Iowa, United States

Mercy Hospital; 🇺🇸 Cedar Rapids, Iowa, United States

MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford; 🇺🇸 Biddeford, Maine, United States

Saint Joseph Mercy Brighton; 🇺🇸 Brighton, Michigan, United States

Genesee Cancer and Blood Disease Treatment Center; 🇺🇸 Flint, Michigan, United States

Trinity Health IHA Medical Group Hematology Oncology - Canton; 🇺🇸 Canton, Michigan, United States

Great Lakes Cancer Management Specialists-Doctors Park; 🇺🇸 East China Township, Michigan, United States

Trinity Health Saint Mary Mercy Livonia Hospital; 🇺🇸 Livonia, Michigan, United States

Saint John Macomb-Oakland Hospital; 🇺🇸 Warren, Michigan, United States

Ascension Saint Mary's Hospital; 🇺🇸 Saginaw, Michigan, United States

University of Kansas Cancer Center - Lee's Summit; 🇺🇸 Lee's Summit, Missouri, United States

Essentia Health Sandstone; 🇺🇸 Sandstone, Minnesota, United States

University of Kansas Cancer Center at North Kansas City Hospital; 🇺🇸 North Kansas City, Missouri, United States

Saint Francis Medical Center; 🇺🇸 Cape Girardeau, Missouri, United States

Siteman Cancer Center at West County Hospital; 🇺🇸 Creve Coeur, Missouri, United States

Siteman Cancer Center-South County; 🇺🇸 Saint Louis, Missouri, United States

Parkland Health Center - Farmington; 🇺🇸 Farmington, Missouri, United States

Cancer Institute at Saint Francis Hospital; 🇺🇸 East Hills, New York, United States

Mary Imogene Bassett Hospital; 🇺🇸 Cooperstown, New York, United States

Arnot Ogden Medical Center/Falck Cancer Center; 🇺🇸 Elmira, New York, United States

Good Samaritan Hospital Medical Center; 🇺🇸 West Islip, New York, United States

Columbus Oncology and Hematology Associates Inc; 🇺🇸 Columbus, Ohio, United States

Cancer Centers of Southwest Oklahoma Research; 🇺🇸 Lawton, Oklahoma, United States

Trinity's Tony Teramana Cancer Center; 🇺🇸 Steubenville, Ohio, United States

UPMC-Heritage Valley Health System Beaver; 🇺🇸 Beaver, Pennsylvania, United States

UPMC Altoona; 🇺🇸 Altoona, Pennsylvania, United States

UPMC Cancer Centers - Arnold Palmer Pavilion; 🇺🇸 Greensburg, Pennsylvania, United States

UPMC Cancer Center-Natrona Heights; 🇺🇸 Natrona Heights, Pennsylvania, United States

UPMC Hillman Cancer Center - Part of Frick Hospital; 🇺🇸 Mount Pleasant, Pennsylvania, United States

Divine Providence Hospital; 🇺🇸 Williamsport, Pennsylvania, United States

WellSpan Health-York Cancer Center; 🇺🇸 York, Pennsylvania, United States

AnMed Health Cancer Center; 🇺🇸 Anderson, South Carolina, United States

Prisma Health Greenville Memorial Hospital; 🇺🇸 Greenville, South Carolina, United States

The Don and Sybil Harrington Cancer Center; 🇺🇸 Amarillo, Texas, United States

Prisma Health Cancer Institute - Seneca; 🇺🇸 Seneca, South Carolina, United States

Prisma Health Cancer Institute - Faris; 🇺🇸 Greenville, South Carolina, United States

Edwards Comprehensive Cancer Center; 🇺🇸 Huntington, West Virginia, United States

Duluth Clinic Ashland; 🇺🇸 Ashland, Wisconsin, United States

Aurora Cancer Care-Grafton; 🇺🇸 Grafton, Wisconsin, United States

Saint Vincent Hospital Cancer Center at Saint Mary's; 🇺🇸 Green Bay, Wisconsin, United States

Saint Vincent Hospital Cancer Center Green Bay; 🇺🇸 Green Bay, Wisconsin, United States

Saint Vincent Hospital Cancer Center at Oconto Falls; 🇺🇸 Oconto Falls, Wisconsin, United States

Aurora Medical Center in Summit; 🇺🇸 Summit, Wisconsin, United States

Truman Medical Centers; 🇺🇸 Kansas City, Missouri, United States

University of Kansas Cancer Center - North; 🇺🇸 Kansas City, Missouri, United States

Ralph H Johnson VA Medical Center; 🇺🇸 Charleston, South Carolina, United States

University of Kansas Cancer Center-Overland Park; 🇺🇸 Overland Park, Kansas, United States

Regions Hospital; 🇺🇸 Saint Paul, Minnesota, United States

Genesys Hurley Cancer Institute; 🇺🇸 Flint, Michigan, United States

Hurley Medical Center; 🇺🇸 Flint, Michigan, United States

Bronson Methodist Hospital; 🇺🇸 Kalamazoo, Michigan, United States

Ascension Borgess Cancer Center; 🇺🇸 Kalamazoo, Michigan, United States

Saint Luke's Cancer Institute - Meridian; 🇺🇸 Meridian, Idaho, United States

Oncology Hematology Associates of Saginaw Valley PC; 🇺🇸 Saginaw, Michigan, United States

Academic Hematology Oncology Specialists; 🇺🇸 Grosse Pointe Woods, Michigan, United States

Huron Gastroenterology PC; 🇺🇸 Ypsilanti, Michigan, United States

Bronson Battle Creek; 🇺🇸 Battle Creek, Michigan, United States

Saint Luke's Cancer Institute - Fruitland; 🇺🇸 Fruitland, Idaho, United States

CTCA at Western Regional Medical Center; 🇺🇸 Goodyear, Arizona, United States

MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford; 🇺🇸 Sanford, Maine, United States

Kaiser Permanente-Gaithersburg Medical Center; 🇺🇸 Gaithersburg, Maryland, United States

Bayhealth Hospital Kent Campus; 🇺🇸 Dover, Delaware, United States

Beebe South Coastal Health Campus; 🇺🇸 Frankford, Delaware, United States

Helen F Graham Cancer Center; 🇺🇸 Newark, Delaware, United States

Louisiana Hematology Oncology Associates LLC; 🇺🇸 Baton Rouge, Louisiana, United States

Mount Sinai Medical Center; 🇺🇸 Miami Beach, Florida, United States

Veterans Affairs Connecticut Healthcare System-West Haven Campus; 🇺🇸 West Haven, Connecticut, United States

Saint Luke's Cancer Institute - Nampa; 🇺🇸 Nampa, Idaho, United States

Saint Luke's Cancer Institute - Boise; 🇺🇸 Boise, Idaho, United States

Saint Luke's Cancer Institute - Twin Falls; 🇺🇸 Twin Falls, Idaho, United States

Beebe Health Campus; 🇺🇸 Rehoboth Beach, Delaware, United States

Bayhealth Hospital Sussex Campus; 🇺🇸 Milford, Delaware, United States

Kaiser Permanente-Capitol Hill Medical Center; 🇺🇸 Washington, District of Columbia, United States

Great Lakes Cancer Management Specialists-Macomb Medical Campus; 🇺🇸 Macomb, Michigan, United States

West Michigan Cancer Center; 🇺🇸 Kalamazoo, Michigan, United States

Marie Yeager Cancer Center; 🇺🇸 Saint Joseph, Michigan, United States

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center; 🇺🇸 Grosse Pointe Woods, Michigan, United States

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital; 🇺🇸 Chelsea, Michigan, United States

Kaiser Permanente - Kensington Medical Center; 🇺🇸 Kensington, Maryland, United States

Addison Gilbert Hospital; 🇺🇸 Gloucester, Massachusetts, United States

Ascension Providence Hospitals - Southfield; 🇺🇸 Southfield, Michigan, United States

Dartmouth Hitchcock Medical Center; 🇺🇸 Lebanon, New Hampshire, United States

Genesee Hematology Oncology PC; 🇺🇸 Flint, Michigan, United States

Ascension Saint John Hospital; 🇺🇸 Detroit, Michigan, United States

Trinity Health IHA Medical Group Hematology Oncology - Brighton; 🇺🇸 Brighton, Michigan, United States

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus; 🇺🇸 Ypsilanti, Michigan, United States

Saint Joseph Mercy Chelsea; 🇺🇸 Chelsea, Michigan, United States

William E Kahlert Regional Cancer Center/Sinai Hospital; 🇺🇸 Westminster, Maryland, United States

Beverly Hospital; 🇺🇸 Beverly, Massachusetts, United States

UMass Memorial Medical Center - University Campus; 🇺🇸 Worcester, Massachusetts, United States

University of Mississippi Medical Center; 🇺🇸 Jackson, Mississippi, United States

Sparrow Hospital; 🇺🇸 Lansing, Michigan, United States

Great Lakes Cancer Management Specialists-Macomb Professional Building; 🇺🇸 Warren, Michigan, United States

Lahey Hospital and Medical Center; 🇺🇸 Burlington, Massachusetts, United States

Bhadresh Nayak MD PC-Sterling Heights; 🇺🇸 Sterling Heights, Michigan, United States

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States

Gundersen Lutheran Medical Center; 🇺🇸 La Crosse, Wisconsin, United States

Ascension Saint Joseph Hospital; 🇺🇸 Tawas City, Michigan, United States

Mercyhealth Hospital and Cancer Center - Janesville; 🇺🇸 Janesville, Wisconsin, United States

OptumCare Cancer Care at Charleston; 🇺🇸 Las Vegas, Nevada, United States

Saint Joseph Mercy Canton; 🇺🇸 Canton, Michigan, United States

Lahey Medical Center-Peabody; 🇺🇸 Peabody, Massachusetts, United States

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States

Fox Chase Cancer Center; 🇺🇸 Philadelphia, Pennsylvania, United States

Prisma Health Cancer Institute - Spartanburg; 🇺🇸 Boiling Springs, South Carolina, United States

West Virginia University Healthcare; 🇺🇸 Morgantown, West Virginia, United States

West Virginia University Charleston Division; 🇺🇸 Charleston, West Virginia, United States

Prisma Health Cancer Institute - Butternut; 🇺🇸 Greenville, South Carolina, United States

Prisma Health Cancer Institute - Easley; 🇺🇸 Easley, South Carolina, United States

Aurora Saint Luke's Medical Center; 🇺🇸 Milwaukee, Wisconsin, United States

Sanford USD Medical Center - Sioux Falls; 🇺🇸 Sioux Falls, South Dakota, United States

Aurora West Allis Medical Center; 🇺🇸 West Allis, Wisconsin, United States

Prisma Health Cancer Institute - Eastside; 🇺🇸 Greenville, South Carolina, United States

Saint Vincent Hospital Cancer Center at Sturgeon Bay; 🇺🇸 Sturgeon Bay, Wisconsin, United States

Froedtert Menomonee Falls Hospital; 🇺🇸 Menomonee Falls, Wisconsin, United States

Froedtert West Bend Hospital/Kraemer Cancer Center; 🇺🇸 West Bend, Wisconsin, United States

University of Kentucky/Markey Cancer Center; 🇺🇸 Lexington, Kentucky, United States

University of Wisconsin Carbone Cancer Center; 🇺🇸 Madison, Wisconsin, United States

Cancer Center of Kansas-Wichita Medical Arts Tower; 🇺🇸 Wichita, Kansas, United States

Ascension Via Christi Hospitals Wichita; 🇺🇸 Wichita, Kansas, United States

Cancer Center of Kansas - Wichita; 🇺🇸 Wichita, Kansas, United States

University of New Mexico Cancer Center; 🇺🇸 Albuquerque, New Mexico, United States

Presbyterian Kaseman Hospital; 🇺🇸 Albuquerque, New Mexico, United States

University of Rochester; 🇺🇸 Rochester, New York, United States

Mercy Cancer Center-West Lakes; 🇺🇸 Clive, Iowa, United States

Genesis Healthcare System Cancer Care Center; 🇺🇸 Zanesville, Ohio, United States

UPMC Cancer Center-Washington; 🇺🇸 Washington, Pennsylvania, United States